Patents Issued in May 2, 2017
-
Patent number: 9636383Abstract: A synthetic platelet includes a biocompatible flexible nanoparticle that includes an outer surface and a plurality of peptides conjugated to the surface, the peptides including a plurality of von Willebrand factor-binding peptides (VBPs), collagen-binding peptides (CBPs) and an active platelet GPIIb-IIIa-binding peptides (GBPs).Type: GrantFiled: August 14, 2015Date of Patent: May 2, 2017Assignee: Case Western Reserve UniversityInventors: Anirban Sen Gupta, Madhumitha Ravikumar
-
Patent number: 9636384Abstract: This document relates to methods and materials involved in delivering molecules to a mammal. For example, methods and materials for using nanoparticles to increase the half-life and the bioavailability of molecules administered to a mammal are provided.Type: GrantFiled: April 5, 2010Date of Patent: May 2, 2017Assignee: Mayo Foundation For Medical Education and ResearchInventors: Christopher B. Eckman, Aimee R. Herdt
-
Patent number: 9636385Abstract: Provided is a method of treatment for reducing fibrosis involving administering purified collagenase into an anterior chamber of an eye of a human patient.Type: GrantFiled: October 24, 2013Date of Patent: May 2, 2017Assignee: The Research Foundation for The State University of New YorkInventor: Robert Honkanen
-
Patent number: 9636386Abstract: Provided herein are attenuated Salmonella bacteria for expressing autoantigen alone or in combination with an immunomodulator, as well as methods of using these bacteria to treat various autoimmune disorders.Type: GrantFiled: March 14, 2014Date of Patent: May 2, 2017Assignee: CITY OF HOPEInventors: Mohamed I. Husseiny Elsayed, Kevin Ferreri
-
Patent number: 9636387Abstract: The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer.Type: GrantFiled: August 18, 2014Date of Patent: May 2, 2017Assignee: Governing Council of the University of TorontoInventors: Aws Abdul-Wahid, Jean Gariépy
-
Patent number: 9636388Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: GrantFiled: May 19, 2016Date of Patent: May 2, 2017Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Meghan Gentilini, Vijay Ramiya, Marina Victor Abdelmaseeh Bastawrous
-
Patent number: 9636389Abstract: The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and Lawsonia intracellularis (L. intracellularis) antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against Porcine Circovirus Associated Diseases (PCVAD) and L. intracellularis associated diseases. In particular, the present invention provides a method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by L. intracellularis, or a method for reduction of clinical symptoms caused by or associated with a PCV2 and L. intracellularis infection, comprising the step of administering an effective amount of PCV2 antigen and L. intracellularis antigen to an animal in need of such treatment.Type: GrantFiled: July 28, 2015Date of Patent: May 2, 2017Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Vicky Fachinger, Knut Elbers
-
Patent number: 9636390Abstract: A vaccine for protection against multiple serotypes of Shigella sp., comprising a putative heat shock protein (EL PGI II), and Hypothetical Protein (EL PGIV) is provided.Type: GrantFiled: November 19, 2013Date of Patent: May 2, 2017Assignees: Indian Council of Medical Research, Post Graduate Institute of Medical Education and Research (PGIMER)Inventors: Neelam Taneja, Sapna Pahil, Meera Sharma
-
Patent number: 9636391Abstract: Provided is a pharmaceutical composition that includes one or more inactivated Mycobacterium spp., which are preferably inactivated using gamma irradiation, and which is then formulated for mucosal or pulmonary delivery to a subject. The pharmaceutical compositions are useful for preventing or treating mycobacterium-associated infections in a subject, including a human subject.Type: GrantFiled: December 5, 2014Date of Patent: May 2, 2017Assignee: Mico Bio, Inc.Inventors: Jason Fisher, Jennifer Lighter
-
Patent number: 9636392Abstract: The present invention provides an improved method of producing a capsular polysaccharide having a pneumococcal serotype. The method according to the present invention includes a step of additionally culturing bacterial cells producing a pneumococcal serotype without pH adjustment, thereby removing a protein precipitation process by acidification with a pH adjuster.Type: GrantFiled: September 6, 2013Date of Patent: May 2, 2017Assignee: SK CHEMICAL CO., LTD.Inventors: Jin-Hwan Shin, Mahn-Hoon Park, Hun Kim, Myeong-Ju Noh, Su-Jin Park
-
Patent number: 9636393Abstract: International patent application WO99/61053 discloses immunogenic compositions that comprise N. meningitidis serogroup C oligosaccharide conjugated to a carrier, in combination with N. meningitidis serogroup B outer membrane protein. These are disclosed in the present application in combination with further Neisserial proteins and/or protective antigens against other pathogenic organisms (e.g. Haemophilus influenzae, DTP, HBV, etc.).Type: GrantFiled: November 29, 2000Date of Patent: May 2, 2017Assignee: GlaxoSmithKline Biologicals SAInventors: Marzia Monica Giuliani, Mariagrazia Pizza, Rino Rappuoli
-
Patent number: 9636394Abstract: A process for producing a split influenza virus preparation or subunit influenza preparation comprising the steps of: (i) providing a whole virus preparation; (ii) splitting the whole virus preparation in the presence of a first detergent; (iii) adding t-octylphenoxypolyethoxyethanol (TRITON X-100™) to the resulting split virus preparation; and (iv) filtering the split virus preparation.Type: GrantFiled: October 25, 2010Date of Patent: May 2, 2017Assignees: GLAXOSMITHKLINE BIOLOGICALS SA, GLAXOSMITHKLINE BIOLOGICALS, NIEDERLASSUNG DER SMITHKLINE BEECHAM PHARMA GMBH & CO KG.Inventors: Erik Jozef D'Hondt, Hans Bernd Engelmann
-
Patent number: 9636395Abstract: The present invention relates to the use of at least one attenuated measles virus for the manufacture of a medicament intended for treating malignant mesothelioma in an individual.Type: GrantFiled: April 8, 2015Date of Patent: May 2, 2017Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Anne Gauvrit, Frédéric Tangy, Marc Gregoire
-
Patent number: 9636396Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.Type: GrantFiled: December 7, 2012Date of Patent: May 2, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SUD XI, INSITUT GUSTAVE ROUSSY, VIROXIS S.A.S.Inventor: Thierry Heidmann
-
Patent number: 9636397Abstract: The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide. A vaccine composition is also provided for that generally includes the vaccine composition of the present disclosure and a DNA component. A method for vaccinating animals and humans utilizing the adjuvant composition of the present disclosure is also provided.Type: GrantFiled: March 24, 2016Date of Patent: May 2, 2017Assignee: Vaxliant, LLCInventors: Timothy J Miller, Mary Ann Pfannenstiel
-
Patent number: 9636398Abstract: Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.Type: GrantFiled: December 13, 2012Date of Patent: May 2, 2017Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.Inventors: Gangamani S. Beligere, Shamila Manoj, Elaine M. Brate, Frank C. Grenier, David J. Hawksworth, Robert N. Ziemann, Larry G. Birkenmeyer, Bernhard Mueller, Andreas Popp, Susan Brophy
-
Patent number: 9636399Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: July 27, 2015Date of Patent: May 2, 2017Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 9636400Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.Type: GrantFiled: May 10, 2016Date of Patent: May 2, 2017Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
-
Patent number: 9636401Abstract: A flexible or elastic brachytherapy strand that includes an imaging marker and/or a therapeutic, diagnostic or prophylactic agent such as a drug in a biocompatible carrier that can be delivered to a subject upon implantation into the subject through the bore of a brachytherapy implantation needle has been developed. Strands can be formed as chains or continuous arrays of seeds up to 50 centimeters or more, with or without spacer material, flaccid, rigid, or flexible.Type: GrantFiled: August 29, 2014Date of Patent: May 2, 2017Assignee: Microspherix LLCInventor: Edward J. Kaplan
-
Patent number: 9636402Abstract: A flexible or elastic brachytherapy strand that includes an imaging marker and/or a therapeutic, diagnostic or prophylactic agent such as a drug in a biocompatible carrier that can be delivered to a subject upon implantation into the subject through the bore of a brachytherapy implantation needle has been developed. Strands can be formed as chains or continuous arrays of seeds up to 50 centimeters or more, with or without spacer material, flaccid, rigid, or flexible.Type: GrantFiled: May 13, 2015Date of Patent: May 2, 2017Assignee: Microspherix LLCInventor: Edward J. Kaplan
-
Patent number: 9636403Abstract: A composition for treating ear infections in animals includes an antifungal agent, an antibiotic agent, a steroidal anti-inflammatory agent, and an acid dissolved to form a liquid. The acid aids in keeping the steroidal anti-inflammatory agent in solution, and enhances the bactericidal effect of the composition. The method of preparing such composition includes dissolving the antifungal agent, steroidal anti-inflammatory agent, and acid in dehydrated alcohol, dissolving the antibiotic agent in propylene glycol, combining the two solutions together, heating the combination and then cooling the composition. Several drops of the composition are applied at least twice per day to the affected area of the animal's ear.Type: GrantFiled: August 1, 2011Date of Patent: May 2, 2017Assignee: Diamondback Drugs of Delaware, L.L.C.Inventors: Rory J Albert, Michael R. Blaire
-
Patent number: 9636404Abstract: The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.Type: GrantFiled: May 13, 2014Date of Patent: May 2, 2017Assignee: Vision Global Holdings Ltd.Inventors: Bing Lou Wong, Norman Fung Man Wai, Sui Yi Kwok, Man Kin Wong, Cornelia Wing Yin Man
-
Patent number: 9636405Abstract: A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of less than 0.9 or about 0.9 to about 0.7 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.Type: GrantFiled: March 11, 2013Date of Patent: May 2, 2017Assignee: FOAMIX PHARMACEUTICALS LTD.Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
-
Patent number: 9636406Abstract: The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.Type: GrantFiled: February 24, 2016Date of Patent: May 2, 2017Assignee: Intensity Therapeutics, Inc.Inventor: Lewis H. Bender
-
Patent number: 9636407Abstract: A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture.Type: GrantFiled: December 21, 2012Date of Patent: May 2, 2017Assignee: FRESENIUS KABI USA, LLCInventors: John Zhiqiang Jiang, Arunya Usayapant, David Bowman, Keith Kwok, Joel Peterson
-
Patent number: 9636408Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.Type: GrantFiled: March 14, 2014Date of Patent: May 2, 2017Assignee: TONIX PHARMA HOLDINGS LIMITEDInventors: Marino Nebuloni, Patrizia Colombo
-
Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters
Patent number: 9636409Abstract: Covalent conjugates of an ?,?-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the ?,?-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells, as in the following compound:Type: GrantFiled: February 8, 2016Date of Patent: May 2, 2017Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Alan Hastings Drummond, Alan Hornsby Davidson, David Festus Charles Moffat, Alastair David Graham Donald, Stephen John Davies -
Patent number: 9636410Abstract: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.Type: GrantFiled: July 6, 2012Date of Patent: May 2, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Luis Brito, Michelle Chan, Andrew Geall, Derek O'Hagan, Manmohan Singh
-
Patent number: 9636411Abstract: Described herein are processes of making biocompatible water-soluble polymers conjugates. In particular, large scale processes of making poly(L-?-glutamyl-glutamate) conjugates that can be useful for a variety of drug delivery applications are described herein.Type: GrantFiled: April 26, 2013Date of Patent: May 2, 2017Assignee: Nitto Denko CorporationInventors: Hao Bai, Kwok Yin Tsang, Yi Jin, Lei Yu
-
Patent number: 9636412Abstract: Conjugates of an anti-TNF antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.Type: GrantFiled: August 5, 2015Date of Patent: May 2, 2017Assignee: Nektar TherapeuticsInventors: Mary J. Bossard, Gayle Stephenson-Phillips
-
Patent number: 9636413Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.Type: GrantFiled: November 14, 2013Date of Patent: May 2, 2017Assignee: ENDOCYTE, INC.Inventors: Iontcho Radoslavov Vlahov, Joseph Anand Reddy, Alicia Bloomfield, Ryan Dorton, Melissa Nelson, Marilynn Vetzel, Christopher Paul Leamon
-
Patent number: 9636414Abstract: The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation.Type: GrantFiled: December 15, 2011Date of Patent: May 2, 2017Assignee: BIONTECH AGInventor: Steve Pascolo
-
Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
Patent number: 9636415Abstract: A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.Type: GrantFiled: March 8, 2013Date of Patent: May 2, 2017Assignee: S-TARGET THERAPEUTICS GMBHInventors: Geert Mudde, Gottfried Himmler -
Patent number: 9636416Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: October 31, 2014Date of Patent: May 2, 2017Assignee: Bioverativ Therapeutics Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitoni, Susan C. Low
-
Patent number: 9636417Abstract: The invention is based on the identification of aminopeptidase N (APN) as the receptor for F4 fimbriae of enterotoxigenic E. coli (ETEC). Based on the observation that oral administration of F4 fimbriae induces a protective intestinal mucosal immune response against a subsequent challenge with F4 ETEC, and the observation that the internalization of said F4fimbriae is clathrin-mediated, the present invention provides the characterization of APN as a target useful in: in an in vitro assay to screen for molecules that are capable to mimic the clathrin-mediated F4 endocytosis; in an in vitro assay to screen for molecules that are capable to modulate the binding of F4 fimbriae with APN; in the development of a carrier for the delivery of antigens/therapeutics, i.e. immunomodulators to the intestinal submucosa or the intestinal mucosa-associated lymphoid tissue, wherein said carrier comprises an APN specific target molecule that mimics the clathrin-mediated F4 endocytosis.Type: GrantFiled: January 15, 2015Date of Patent: May 2, 2017Assignee: Universiteit GentInventors: Kristien Rasschaert, Bruno Goddeeris, Eric Cox, Dieter Deforce
-
Patent number: 9636418Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: March 12, 2014Date of Patent: May 2, 2017Assignee: AMGEN INC.Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda
-
Patent number: 9636419Abstract: A method of delivering a cargo agent into cytosol of a cell can include: providing the delivery system of one of the embodiments described herein having the first and second delivery platforms; and administering the delivery system to a cell so as to cause targeting of two features on the cell so as to: cause endocytosis of the first and second delivery platforms of the delivery system into a common endosome, destabilize the endosome of the cell having the delivery system, release the cargo agent from the second linker; and release the cargo agent from the destabilized endosome into cytosol of the cell. A method of treating a disease can include: performing the method of method of delivering a cargo agent into cytosol of a cell in a subject having a disease, wherein the cargo agent is a therapeutic agent for the disease.Type: GrantFiled: October 13, 2014Date of Patent: May 2, 2017Assignees: The Universit of Kansas, Albert Einstein College of Medicine, Inc.Inventors: Blake R. Peterson, Liang Xu, Matthew Levy
-
Patent number: 9636420Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.Type: GrantFiled: July 23, 2009Date of Patent: May 2, 2017Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
-
Patent number: 9636421Abstract: The present invention relates to a compound comprising an alpha-end and an omega-end, the compound comprising on the alpha-end a reactive group Q1 capable of reacting with a functional group F1 present on a biomolecule and on the omega-end a target molecule, the compound further comprising a group according to formula (1) or a salt thereof: Said compound may also be referred to as a linker-conjugate. The invention also relates to a process for the preparation of a bioconjugate, the process comprising the step of reacting a reactive group Q1 of a linker-conjugate according to the invention with a functional group F1 of a biomolecule. The invention further relates to a bioconjugate obtainable by the process according to the invention.Type: GrantFiled: November 23, 2016Date of Patent: May 2, 2017Assignee: Synaffix B.V.Inventors: Jorge Merijn Mathieu Verkade, Maria Antonia Wijdeven, Petrus Josephus Jacobus Maria Van de Sande, Sander Sebastiaan Van Berkel, Floris Louis Van Delft
-
Patent number: 9636422Abstract: A computerized method is disclosed for detecting a brain region with neurodegenerative change and also a brain region with vascular change in the brain of a patient and also an imaging arrangement suitable for this.Type: GrantFiled: July 24, 2008Date of Patent: May 2, 2017Assignee: SIEMENS AKTIENGESELLSCHAFTInventors: Thorsten Feiweier, Diana Martin, Günther Platsch, Sebastian Schmidt, Kristin Schmiedehausen, Michael Szimtenings
-
Patent number: 9636423Abstract: The present invention provides methods and compositions based on optical sensor conjugates that are useful for detecting reactive oxygen, reactive nitrogen, or both species that are a direct result of inflammation caused by tissue damage.Type: GrantFiled: June 2, 2011Date of Patent: May 2, 2017Assignee: The General Hospital CorporationInventors: Scott A. Hilderbrand, Ralph Weissleder, Peter Panizzi, Jason R. McCarthy
-
Patent number: 9636424Abstract: The present invention provides a method of optical electrophysiological probing, including: providing a fluorescing chemical probe; contacting a thick portion of tissue with the fluorescing chemical probe to create a thick portion of treated tissue; applying a first range of wavelengths of electromagnetic radiation to the treated portion of tissue; and detecting a plurality of depth-specific emission wavelengths emitted from the thick portion of treated tissue.Type: GrantFiled: May 19, 2016Date of Patent: May 2, 2017Assignees: The Research Foundation of State University of New York, University of ConnecticutInventors: Arkady M. Pertsov, Arvydas Matiukas, Leslie M. Loew, Joseph P. Wuskell
-
Patent number: 9636425Abstract: A device and method for staining the eye of a patient in need of the same includes the introduction, onto the surface of the eye, of a dry powder form at a dye suitable for staining the eye. The dry powder form of the dye is introduced onto the surface of the eye without the use of a substrate at or near the eye's surface.Type: GrantFiled: September 18, 2012Date of Patent: May 2, 2017Assignee: Focal Point Technologies, LLCInventor: Amir Sahba Jalali
-
Patent number: 9636426Abstract: The present invention provides a fluorescent molecular probe for efficient fluorescent detection (visualization) of tumors or for implementing fluorescent detection and photodynamic treatment, more specifically, the present invention provides a macromolecular fluorescent molecular probe for fluorescent detection of tumor, comprising a complex comprising a fluorescent molecule and a biocompatibie macromolecule.Type: GrantFiled: September 5, 2012Date of Patent: May 2, 2017Inventors: Hiroshi Maeda, Makoto Hashizume, Jun Fang, Hideaki Nakamura, Haibo Qin, Steffen Hackbarth, Masaharu Murata
-
Patent number: 9636427Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.Type: GrantFiled: April 27, 2016Date of Patent: May 2, 2017Assignee: GUERBETInventors: Dominique Meyer, Claire Corot, Marc Port, Vincent Barbotin, Bruno Bonnemain
-
Patent number: 9636428Abstract: The present disclosure is directed to sulfonic esters of metal oxides including those of formulas I and II:Type: GrantFiled: September 22, 2014Date of Patent: May 2, 2017Assignees: California Institute of Technology, Children's Hospital of Los AngelesInventors: Carl M. Blumenfeld, Karn Sorasaenee, Harry B. Gray, Robert H. Grubbs
-
Patent number: 9636429Abstract: A bracket and tray connection system includes a tray with a plurality of connector holes positioned therein, wherein the tray has an upper surface. A bracket has a base surface positioned proximate to an upper surface of the tray. At least one fastening tab is formed on the base surface of the bracket, wherein the fastening tab extends away from the base surface and through at least one of the connector holes within the tray. An interior corner pocket is formed by the fastening tab and located at least partially between the base surface and the fastening tab. An exterior corner of at least one of the connector holes is positioned with the interior corner pocket. A retainer structure is formed on the base surface of the bracket, wherein the retainer structure engages with the tray to retain the exterior corner positioned within the interior corner pocket.Type: GrantFiled: November 12, 2014Date of Patent: May 2, 2017Assignee: Symmetry Medical Manufacturing, Inc.Inventors: Robert Cushion, Jason Hawkes
-
Patent number: 9636430Abstract: A cartridge for a microfluidic delivery system is defined by a longitudinal axis. The cartridge includes a reservoir for containing a fluid composition. The cartridge also includes a nozzle operatively connected with the reservoir. The nozzle is in fluid communication with the reservoir for releasing the fluid composition. The cartridge includes an outer cover operatively connected with the reservoir. The outer cover comprises an orifice that is adjacent to the nozzle. An air flow path is formed by a gap between the reservoir and the outer cover.Type: GrantFiled: September 16, 2015Date of Patent: May 2, 2017Assignee: The Procter & Gamble CompanyInventors: Dana Paul Gruenbacher, Martin Diehl, Jannik Scheele, Joseph Edward Scheffelin, Uwe Schober
-
Patent number: 9636431Abstract: A dispenser capable of dispensing a fluid via a vertically-oriented piezo device comprises a reservoir containing a fluid to be dispensed, an outlet at a base portion of the reservoir, leading to a dispensing port that comprises a piezo element drivable to vibrate and thereby dispense fluid from the dispensing port, a bleed tube communicating at one end with the dispensing port, extending therefrom to a location above the dispensing port, and including a selectively closeable valve, and a source of below-atmospheric pressure to the portion of the reservoir above the fluid. Embodiments of refills suitable for such a dispensing apparatus are also described.Type: GrantFiled: August 22, 2012Date of Patent: May 2, 2017Assignee: Vectair Systems LimitedInventors: Matthew Teeling, Paul Wonnacott
-
Patent number: 9636432Abstract: The presently claimed invention provides a photocatalytic air purification unit, comprising a fin structure and an UV lamp. The fin structure comprises a plurality of fins coated with a layer of photocatalyst, and said fin structure is able to increase the surface area for photocatalyst coating, ultimately increasing air pollutant removal efficiency with minimum air resistance. The air purification unit of the present invention is preferably installed in a HVAC system.Type: GrantFiled: January 29, 2014Date of Patent: May 2, 2017Assignee: NANO AND ADVANCED MATERIALS INSTITUTE LIMITEDInventor: Lok Hang Keung